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ABSTRACT:
Oncogenic fusion proteins, such as EWS-FLI1, are excellent therapeutic targets 
as they are only located within the tumor. However, there are currently no 
agents targeted toward transcription factors, which are often considered to be 
‘undruggable.’ A considerable body of evidence is accruing that refutes this claim 
based upon the intrinsic disorder of transcription factors. Our previous studies 
show that RNA Helicase A (RHA) enhances the oncogenesis of EWS-FLI1, a putative 
intrinsically disordered protein. Interruption of this protein-protein complex by 
small molecule inhibitors validates this interaction as a unique therapeutic target.  
Single enantiomer activity from a chiral compound has been recognized as strong 
evidence for specificity in a small molecule-protein interaction. Our compound, 
YK-4-279, has a chiral center and can be separated into two enantiomers by chiral 
HPLC. We show that there is a significant difference in activity between the two 
enantiomers. (S)-YK-4-279 is able to disrupt binding between EWS-FLI1 and RHA 
in an immunoprecipitation assay and blocks the transcriptional activity of EWS-
FLI1, while (R)-YK-4-279 cannot. Enantiospecific effects are also established in 
cytotoxicity assays and caspase assays, where up to a log-fold difference is seen 
between (S)-YK-4-279 and the racemic YK-4-279. Our findings indicate that only 
one enantiomer of our small molecule is able to specifically target a protein-protein 
interaction. This work is significant for its identification of a single enantiomer effect 
upon a protein interaction suggesting that small molecule targeting of intrinsically 
disordered proteins can be specific. Furthermore, proving YK-4-279 has only one 
functional enantiomer will be helpful in moving this compound towards clinical trials.
INTRODUCTION
Transcription factors are often considered to be 
‘undruggable,’ despite being promising therapeutic 
targets. Transcription factors are the driving force in 
many cancers and are the “bottleneck” of many signaling 
cascades[1]. Many oncogenic transcription factors result 
from chromosomal translocations that are unique anti-
cancer targets. ETS family translocations occur in several 
cancers, including prostate, malignant melanoma of soft 
parts, myxoid liposarcomas, desmoplastic small round cell 
tumors, and Ewing’s sarcoma family of tumors (ESFT)Oncotarget 2012; 3:  172-182 173 www.impactjournals.com/oncotarget
[2]. Ninety-five percent of ESFT cases contain a balanced 
t(11;22) or t(21;22) rearrangement, combining the amino-
terminus of EWS to the carboxyl-terminus of FLI1 or 
ERG, both of which contain the highly conserved ets 
DNA binding domain[3]. Currently, there are no clinically 
available targeted agents that inhibit these unique tumor-
specific proteins.
Unlike targeting an enzyme at the ATP binding site, 
development of a therapeutic target for a transcription 
factor requires very specific disruption of a DNA-protein 
or protein-protein interaction[4]. EWS-FLI1 is predicted 
to be an intrinsically disordered protein (IDP), which is 
a protein lacking stable secondary or tertiary structures 
under physiological conditions[5]. IDPs often have a great 
potential for binding to small molecules due to higher 
induced-fit sampling properties and have the potential 
for multiple binding sites to small molecules[6]. IDPs 
have already been targeted for drug discovery, such as 
the kinase and phosphorylation sites located within areas 
of intrinsic disorder[7]. The c-Myc oncoprotein can be 
inhibited by small molecules that bind to the disordered 
region of c-Myc[8, 9]. EWS-FLI1 requires disorder for 
maximal transactivation of transcription[10] and the 
disordered nature of the transcription factor facilitates the 
protein-protein complexes that lead to oncogenesis[11]. 
Oncogenesis of EWS-FLI1 requires protein 
partnering with RNA Helicase A (RHA), which is 
necessary to enhance the transformation of EWS-
FLI1[12].  The  purification  of  recombinant  EWS-
FLI1[13] allowed for the screening of a library of small 
molecules with surface plasmon resonance to identify 
compounds with direct binding[14]. The small molecule 
lead compound and its derivative, YK-4-279, bind to 
EWS-FLI1 and are able to disrupt the EWS-FLI1/RHA 
interaction. Treatment with YK-4-279 specifically inhibits 
EWS-FLI1 function both in vivo and in vitro. Our small 
molecule, YK-4-279, is the first molecule to directly target 
EWS-FLI1.
YK-4-279 contains a chiral center. Chiral 
discrimination between enantiomers is extremely 
important, as stereopure drugs can often reduce the total 
dose of drug given and minimize any toxicity resulting 
from the inactive enantiomer[15]. Examples of specificity 
of enantiomers ranges from harmless, such as estrone with 
an inactive (-) form and active (+) form, to penicillamine, 
which is extremely toxic when dosed in the L-form[16]. 
When dosed in the (R)-form, thalidomide acts as a 
sedative, but treatment with the (S)-enantiomer is highly 
teratogenic[17]. However, chiral inversion of thalidomide 
occurs within the body, and both the (S)- and (R)-forms 
are interconverted with both oral and intravenous dosing. 
In 1992, the FDA revised its policy on the registration of 
new drugs, and now requires separate pharmacological, 
pharmacokinetic,  and  toxicological  profiles  for  each 
enantiomer in a racemic mixture[18]. As a result of these 
changes requiring additional toxicology studies of racemic 
compounds, single enantiomer drugs have since dominated 
the pharmaceuticals approved in the United States[19].
In order to evaluate enantiospecific effects of YK-
4-279, we separated both enantiomers to purity and 
tested each in comparison to the racemate. Our results 
indicate a significant difference in activity between the 
two enantiomers. These experiments clarify the activity of 
YK-4-279 based upon its single enantiomer activity and 
contribute to the future clinical development of YK-4-279 
in an era where novel approaches to cancer therapy are 
critical to improving patient care.
Figure 1: YK-4-279 is a chiral molecule and the 
enantiomers were separated to purity. (A) The racemate 
was analyzed using a Chiralpak AD column with 60% 2-propanol 
in heptane with 0.1% TFA as a mobile phase. HPLC analysis 
of racemate clearly identified 2 single enantiomer peaks. (B) 
The enantiomers were crystalized in ethyl acetate and analyzed 
by x-ray crystallography. This resolved crystal shows the (S)-
enantiomer and has an optical rotation of -191.9°. (C) Small 
molecule circular dichroism show 50µM of enantiomers rotate 
plane-polarized light in opposite directions.
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RESULTS
YK-4-279 can be separated into enantiomers
The chiral molecule YK-4-279 was resolved into its 
individual enantiomers using preparative high pressure 
liquid chromatography (HPLC). The analytical trace 
indicates the presence of two enantiomers (Figure 1A). 
The retention time of the first enantiomer is 8.2 minutes, 
while the retention of the second enantiomer is 20.0 
minutes. Conditions from the batch analysis were scaled 
linearly to a 250mm x 77mm preparative column. Aliquots 
of each sample were analyzed by chemical and chiral 
HPLC and mass spectrometry (MS). The HPLC results 
show chemical and chiral purity of both fractions, with 
chemical purity and enantiomeric excess values of >99%. 
MS analyses of the enantiomers are consistent with the 
structure of YK-4-279.
The enantiomers were analyzed for optical rotation 
to determine the polarization angle. The first enantiomer 
to elute from the column has an optical rotation of -191.9°, 
while the second enantiomer rotates the polarized light 
clockwise +192.6°. To further determine the enantiomer 
Figure 2: (S)-YK-4-279 disrupts binding between EWS-FLI1 and RHA. (A) An ELISA assay measures binding between EWS-
FLI1 and RHA. Small molecule (1 – 30µM) was added to EWS-FLI1, followed by the addition of RHA and detection with antibody (**, 
p < 0.05 compared to vehicle control, using a two-tailed Student’s t-test). (B) TC32 cells were treated with 10µM small molecule for 15 
hours. Immunoprecipitation of EWS-FLI1 and RHA was detected via western blot. (C) TC32 cells were treated with 0.3, 1, 3, and 10µM 
of small molecule for 15 hours followed by immunoprecipitation. (D) Immunoblot of 10% input for (C). (E) Densitometry was calculated 
for each band and the ratio RHA to EWS-FLI1 was plotted.
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conformation, crystals were grown in hexane/ethyl acetate. 
Crystals were obtained from both (+) and (-) enantiomers. 
The crystals of both the (+) and (-) enantiomers were 
analyzed by x-ray crystallography. The (+) enantiomer 
has (R)-configuration while the (-) enantiomer has (S)-
configuration  (Figure  1B).  Small  molecule  circular 
dichroism demonstrated the expected mirror image spectra 
of the individual enantiomers, while the racemate had zero 
net rotation of light, indicating a mixture of two isomers in 
equal proportions (Figure 1C). 
(S)-YK-4-279 disrupts binding of RHA with EWS-
FLI1
Previous studies from our group indicate the ability 
of YK-4-279 to block the binding between EWS-FLI1 
and RHA[14]. To determine if enantiospecific blocking of 
this protein-protein interaction occurs, binding between 
EWS-FLI1 and RHA was measured using ELISA. Wells 
coated with EWS-FLI1 were treated with a range from 
1µM to 30µM YK-4-279, (S)-YK-4-279, (R)-YK-4-279, 
or vehicle. Both the racemate and (S)-YK-4-279 are able 
to inhibit the protein-protein interaction with as little as 
1µM small molecule, while (R)-YK-4-279 does not inhibit 
the binding at 30µM (Figure 2A). Multiple ELISA runs 
suggests that (S)-YK-4-279 is only slightly more potent at 
disrupting the complex based upon increased dissociation 
at 1µM.
Next, ESFT cells were treated with YK-4-
279, (S)-YK-4-279, and (R)-YK-4-279, followed by 
immunoprecipitation of EWS-FLI1. We treated TC32 cells 
with 10µM of the racemic or enantiomeric small molecule 
for 15 hours, consistent with the KD value of YK-4-
279[14]. Immunoblotting showed coimmunoprecipitation 
of EWS-FLI1 with RHA in the presence of vehicle or 
(R)-YK-4-279,  but  there  is  a  significant  reduction  in 
complexed RHA in the lysates from cells treated with 
either  YK-4-279  or  (S)-YK-4-279  (Figure  2B).  The 
control IgG lanes do not indicate the pull-down of either 
EWS-FLI1 or RHA. 
To determine the relative potency of YK-4-279 and 
(S)-YK-4-279 to disrupt the binding between EWS-FLI1 
and RHA in ESFT cells, we titrated down the amount of 
small molecule (range = 0.3 to 10µM). TC32 cells were 
treated for 15 hours before immunopreciptation followed 
by immunoblotting for RHA complexes (Figure 2C). 
Cells treated with vehicle or (R)-YK-4-279 were again 
able to pull down RHA, as were cells treated with lower 
doses of YK-4-279 and (S)-YK-4-279, but the binding 
between EWS-FLI1 and RHA was disrupted in a dose-
specific fashion. Treatment did not affect the EWS-FLI1 
or RHA levels (Figure 2D). Densitometry of RHA relative 
to FLI1 was calculated and shows an IC50 of 4.9 µM for 
the racemic and 1.8 µM for the (S)-YK-4-279, with a 
significant difference between vehicle and cells treated 
with 0.3µM (S)-YK-4-279, but not for cells treated with 
the racemic molecule (Figure 2E). The experiment was 
repeated three times and a representative blot is shown.
EWS-FLI1 functional activity is reduced by only 
one enantiomer
Since (S)-YK-4-279 is able to block the binding 
between EWS-FLI1 and RHA, we next investigated 
the ability of the enantiomers to reduce transcriptional 
activity. We transfected COS7 cells with EWS-FLI1 and 
the NR0B1-luciferase reporter plasmid, which contains 
25 EWS-FLI1 DNA-binding sites. YK-4-279 and (S)-
YK-4-279 were able to inhibit EWS-FLI1 transcriptional 
activity in a dose-dependent manner compared to vehicle-
treated cells (Figure 3A), with an IC50 of 0.96µM for 
racemic and 0.75µM for the (S)-enantiomer. At a dose 
Table 1: Cell growth effects of YK-4-279.
Cell Line Histology
µM IC50 at 3 days (+/- SEM)
YK-4-279 Mean (S)-YK-4-279 Mean (R)-YK-4-279 Mean
TC32 ESFT (Type 1) 0.94 (0.14)
1.02 
(0.89)
0.28 (0.06)
0.34 (0.09)
16.30 (4.83)
18.54 
(4.95)
TC71 ESFT (Type 1) 1.83 (0.41) 0.16 (0.02) 20.86 (7.8)
RDES ESFT (Type 2) 1.03 (0.19) 0.87 (0.64) 12.71 (0.11)
SKES ESFT (Type 2) 0.33 (0.03) 0.18 (0.01) 21.01 (3.91)
MMH-ES-1 ESFT (Type 2) 0.94 (0.13) 0.34 (0.08) 25.98 (4.03)
STA-ET 7.2 ESFT (Type 2) 0.60 (0.04) 0.31 (0.01) 21.25 (3.49)
A4573 ESFT (Type 3) 1.46 (0.31) 0.23 (0.08) 11.69 (6.56)
PC3 prostate 4.95 (3.62)
8.88 
(4.23)
3.79 (3.16)
6.86 (3.38)
>30 (0)
27.38 
(1.67)
MCF7 breast 22.82 (7.19) 19.47 (10.53) >30 (0)
MDA-MB-231 breast 0.82 (0.02) 1.17 (0.78) 22.02 (2.43)
PANC1 pancreatic 1.514 (0.6503) 1.69 (0.74) 24.87 (5.13)
ASPC1 pancreatic 14.28 (3.50) 8.16 (6.04) >30 (0)Oncotarget 2012; 3:  172-182 176 www.impactjournals.com/oncotarget
of 0.3µM, luciferase activity was significantly reduced 
from cells treated with (S)-YK-4-279 compared to vehicle 
treated (p < 0.05), while treatment with racemic compared 
to control was not significant. The (R)-enantiomer did not 
show significant reduction from control. Data is averaged 
from three experiments, each performed in triplicate. 
Expression of EWS-FLI1 into COS7 was similar in each 
experiment and a representative Western blot is shown 
(Figure 3B).
EWS-FLI1 has been shown to increase Cyclin D1 
levels by altering the D1b/D1a mRNA level in ESFT 
cells through effects on transcript elongation [20]. Since 
racemic  YK-4-279  significantly  decreases  Cyclin  D1 
levels in TC32 cells[14], we evaluated whether this 
effect was enantiospecific. We treated A673i cells with 
1µM of YK-4-279 or enantiomer for 8 hours and then 
analyzed mRNA for levels of Cyclin D1a and Cyclin 
D1b using quantitative RT-PCR. As a positive control, 
we reduced EWS-FLI1 protein levels in A673i with an 
induced shRNA. With 1µM racemic YK-4-279 treatment, 
there is a reduction in the D1b/D1a levels (Figure 3C). 
The (S)-YK-4-279 is approximately 35% more potent 
at the D1b/D1a reduction than racemic and reduced this 
ratio to a level equivalent to the EWS-FLI1 reduction. 
Consistent with other experiments, the (R)-YK-4-279 
cells maintained a D1b/D1a ratio equivalent to the vehicle 
treated cells. There was no decrease in EWS-FLI1 protein 
expression in cells treated with small molecule (Figure 
3D). Therefore, an enantiospecific effect was seen in a 
second EWS-FLI1 activity assay.
YK-4-279 demonstrates enantiospecific cellular 
effects in EWS-FLI1 containing cells
After determining that (S)-YK-4-279 is able to block 
both the interaction between EWS-FLI1 and RHA as 
well as reduce EWS-FLI1 function while (R)-YK-4-279 
does not, we tested the small molecules for cytotoxicity 
in a panel of ESFT cell lines compared to cell lines that 
lack ets rearrangements. TC32, along with six other cell 
lines expressing EWS-FLI1, were treated with either a 
vehicle or dose of small molecule ranging from 0.1 to 
30µM of compound for three days (Figure 4A). Six of 
these cell lines demonstrated significant cytotoxicity to 
(S)-YK-4-279 compared to racemic (p < 0.05, two-tailed 
Student’s t-test) while the (R)-YK-4-279 enantiomer 
demonstrated  no  specific  toxicity.  Experiments  were 
repeated three times in triplicate and mean IC50 values 
ranged from 0.33µM to 1.83µM for racemic YK-4-279, 
0.16µM to 0.87µM for (S)-YK-4-279, and 11.69µM 
to  25.98µM  for  (R)-YK-4-279  (Figure  4B,  Table  1), 
indicating that (S)-YK-4-279 is the active enantiomer 
in cytotoxicity studies. The effects of the enantiomers 
were also evaluated in a panel of carcinoma cell lines 
lacking  ets rearrangements, including PC3, MCF7, 
MDA-MB-231, PANC1, and ASPC1 (Figure 4C, Table 
1). Average IC50 values for the five non-ESFT cell lines 
were 8.88µM for YK-4-279, 6.86µM for (S)-YK-4-279, 
and >30µM for (R)-YK-4-279. There was no significant 
difference between YK-4-279 and (S)-YK-4-279 in any 
of the non-ESFT cell lines. Therefore the enantiomeric 
Figure 3: EWS-FLI1 activity is altered by (S)- but 
not (R)-enantiomer of YK-4-279. (A) COS7 cells were 
co-transfected with EWS-FLI1 and the EWS-FLI1-responsive 
promoter  NR0B1.  Transfection  assays  were  performed  in 
triplicate (**, p < 0.05 compared to vehicle control, using a 
two-tailed  Student’s  t-test).  (B)  Expression  of  EWS-FLI1  in 
transfected cells was detected by western blot. (C) A673i cells 
were treated with vehicle or 1µM small molecule for 8 hours.   
Control cells were treated with tetracycline for 72 hours to 
reduce EWS-FLI1. qRT-PCR was used to quantify levels of 
CyclinD1a and CyclinD1b mRNA levels. Data is averaged from 
four experiments performed in duplicate (**, p < 0.05 compared 
to vehicle, using a two-tailed Student’s t-test). (E) Immunoblot 
of total cell lysates from one of the four experiments shown in 
(D).
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enhancement of racemic compound to (S)-YK-4-279 
is relatively specific for ESFT cells when compared to 
cancer cell lines lacking EWS-FLI1. 
A panel of Ewing’s and non-Ewing’s cell lines 
were treated with 10µM small molecule for 18 hours 
and assayed for caspase activation. Caspase-3 activity 
increased from 3-fold to 18-fold upon treatment with 
YK-4-279 and approximately 5-fold to 20-fold with 
(S)-YK-4-279 in ESFT cells (TC32, RDES, SKES, 
A4573, MMH-ES-1, STA-ET 7.2), but showed no more 
than a 2-fold increase in apoptosis upon treatment with 
racemic or either enantiomer in non-ESFT cells (MCF7, 
MDA-MB-231, PANC1) (Figure 4D). To show that (S)-
YK-4-279 induces more apoptosis than racemic at lower 
concentrations, we then treated A4573 ESFT cells with 
increasing concentrations of YK-4-279 and (S)-YK-4-279 
for 18 hours (Figure 4E). The slope, representing the rate 
of caspase activity increase, is greater between 0.3 and 
1µM for the (S)-YK-4-279 (m = 7.23 ± 0.32) than the 
racemic (m = 4.43 ± 0.66), but the caspase activity begins 
to reach saturation by 3µM.
(S)-YK-4-279 and (R)-YK-4-279 lack 
racemization in xenograft tumors
Since there was such a clear difference in activity 
between the two enantiomers, we evaluated the potential 
for racemization in whole organisms, including ESFT 
xenografts. YK-4-279 in racemic or purified enantiomeric 
form was administered by intravenous (IV) injection 
or oral gavage to Sprague-Dawley rats (Table 2). As 
expected, since the racemic contains a 1:1 mixture of 
each enantiomer, rats treated with each enantiomer 
individually had 1.8- to 2.3-fold higher concentrations of 
the specific enantiomer in plasma than rats treated with 
the racemic (data not shown). There was no racemization 
indicated in plasma after IV or gavage administration 
since (R)-YK-4-279 was not present in the plasma 
when (S)-YK-4-279 was administered and vice versa 
(Table 2). However, maximum urine concentrations of 
YK-4-279 showed 3.1% of (R)-YK-4-279 when (S)-
YK-4-279 was administered and 6.9 % of (S)-enantiomer 
when (R)-enantiomer was given by IV injection. After 
gavage administration, there were more pronounced 
racemizations with 36.2% of (R)-enantiomer present in 
urine when (S)-enantiomer was administered and 35.7% 
of (S)-enantiomer when (R)-enantiomer was given. The 
A4573 ESFT xenograft model was used to determine if 
any racemization occurred in tumors. (S)-YK-4-279 was 
administered by intravenous (IV) injections to A4573 
tumor-bearing SCID mice. Tumors were resected two 
hours following dosing. At that time, there was no (R)-
YK-4-279 present in tumor tissues after dosing with (S)-
YK-4-279. This lack of racemization within the tumors 
supports development of the (S)-YK-4-279 for clinical 
trials rather than the racemic mixture.
DISCUSSION
We recognized that the small molecule YK-4-279 has 
a chiral center and can be separated into its enantiomers. In 
binding assays and transcriptional assays, (S)-YK-4-279 is 
active and titrations indicate more potency when compared 
to the racemic, while (R)-YK-4-279 is inactive. The 
cellular response to (S)-YK-4-279 demonstrates that it is 
the active enantiomer in both apoptosis and growth assays 
in EWS-FLI1 containing cells. These data characterize the 
enantiospecificty of YK-4-279.
We show that YK-4-279 and (S)-YK-4-279 are 
able to block the EWS-FLI1/RHA interaction, but 
(R)-YK-4-279 cannot. This clearly demonstrates the 
importance of stereochemistry for the targeted disruption 
of small molecule modulators of protein-protein 
interactions. It further supports the hypothesis that small 
molecule interactions with intrinsically disordered proteins 
can  have  significant  specificity,  despite  relatively  low 
affinity[21]. While the structure of the full-length EWS-
FLI1 protein still eludes us due to its intrinsic disorder, the 
functional difference of the two enantiomers may help us 
Table 2: Evaluation of racemization in urine, plasma, and ESFT xenograft tumors.
Route of 
Administration (Dose)
Administered 
Compound
Percent of Enantiomer Present in Biological Matrices
Plasma Urine Tumor
(S)-YK-4-279 (R)-YK-4-279 (S)-YK-4-279 (R)-YK-4-279 (S)-YK-4-279 (R)-YK-4-279
IV (25mg/kg)
(S)-YK-4-279  100 0 96.9 3.1 NA NA
(R)-YK-4-279  0 100 6.9 93.1 NA NA
Gavage (25 mg/kg)
(S)-YK-4-279  100 0 63.8 36.2 NA NA
(R)-YK-4-279  0 100 35.7 64.3 NA NA
IP (75 mg/kg) (S)-YK-4-279 NA NA NA NA 100 0Oncotarget 2012; 3:  172-182 178 www.impactjournals.com/oncotarget
learn more in future studies about the binding relationship 
between EWS-FLI1 and RHA, along with other protein-
protein interactions. 
In order to evaluate the potency of the enantiomers 
towards cells containing EWS-FLI1, we tested a panel 
of cells in cytotoxicity and caspase assays. Our racemic 
small molecule consists of equal parts of the (S)- and 
(R)-enantiomers; thus one would expect a two-fold 
difference in potency between the active enantiomer and 
the racemate. Apoptosis was measured by the activation 
of caspase-3. Through a dose titration, we do see the 
expected two-fold difference in caspase activation between 
ESFT cells treated with YK-4-279 and (S)-YK-4-279 for 
18 hours, at lower concentrations while this saturates at 
the highest concentrations. In each of the ESFT cell lines 
studied for cytotoxicity, (S)-YK-4-279 had a lower IC50 
value than YK-4-279. The actual fold-differences between 
the racemic and the active enantiomer vary from 1.18-fold 
in RDES cells to more than a log-fold difference in TC71 
cells. We tested cells containing all three major variant 
translocation types of Ewing’s sarcoma and this difference 
cannot be attributed to the specific translocation [3]. One 
explanation for this is based on the steep nature of the dose 
response curve, which causes large changes in IC50 based 
on small shifts in viability. Differences in cellular uptake 
or metabolism of YK-4-279, independent of translocation 
type, may also account for the fold-difference between 
racemic and active enantiomer.
The cytotoxicity and caspase results indicate 
that (S)-YK-4-279 is the active enantiomer, and that 
Figure 4: (S)-YK-4-279 is the active enantiomer in cellular assays. (A) A panel of ESFT and non-ESFT cells were treated 
with a dose range of small molecule. Cell viability was measured by WST after 72 hours of treatment. One representative graph from a 
cytotoxicity assay is shown. Graphs show IC50 values for (B) ESFT and (C) non-ESFT cells (**, p < 0.05, using a two-tailed Student’s 
t-test). (D) ESFT and non-ESFT cells were treated with 10µM small molecule for 18 hours. Graph shows fold caspase-3 activity of treated 
cell lysates to control cell lysates. (E) A4573 cells were assayed for caspase-3 activation with increasing concentrations of YK-4-279 and 
(S)-YK-4-279 for 18 hours. For all panels, black bars represent YK-4-279, blue bars represent (S)-YK-4-279, and red bars represent (R)-
YK-4-279.
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it retains specificity to ESFT cells containing an ETS 
family transcription factor in comparison to non-Ewing’s 
cells. Previously, non-transformed cell lines were tested 
with racemic YK-4-279 and found to have IC50 values 
of >30µM[14]. It is important to note that cell growth 
of  both  MDA-MB-231  and  PANC1  cells,  breast  and 
pancreas respectively, were reduced by YK-4-279 and 
(S)-YK-4-279. These cell lines were previously reported 
to have IC50 values of >20µM; however, we received 
these cell lines from a different source than previously 
used and the current clones are more sensitive. Despite 
the increased sensitivity in cytotoxicity studies, the IC50 
values for MDA-MB-231 and PANC1 cells were lower 
for the racemic than the active enantiomer and there 
was no statistical significance between treatments with 
racemic and (S)-YK-4-279. When tested for caspase-3 
activation, neither of these cell lines exhibited more than 
2-fold caspase-activation, in comparison to the ESFT 
cells, which averaged 8.8-fold for YK-4-279 and 10.3-
fold for (S)-YK-4-279 treatment across the panel of six 
cell lines. Although YK-4-279 and the enantiomer may 
have  increased  toxicity  in  MDA-MB-231  and  PANC 
cells, the mechanism of action may be different than in 
ESFT cell lines. Recent studies have identified caspase-
independent cell death factors induced by anticancer 
drugs[22], including apoptosis-inducing factor (AIF)[23], 
endonuclease G[24], and HtrA2[25], which may explain 
the increase in cytotoxicity without caspase activation in 
these two non-ESFT cell lines. Further studies focusing 
on caspase-independent cell death may explain why 
these cells exhibit cytotoxicity toward YK-4-279 but do 
not undergo apoptosis and may inform other potential 
mechanisms of activity.
In preparation for clinical trials, we evaluated the 
potential racemization of YK-4-279. Pharmacokinetic 
studies in rats show no conversion between (S)-
YK-4-279 and (R)-YK-4-279 in the plasma following IV 
dosing and very minimal conversion in urine. However, 
there is increased racemization in urine, but no sign of 
conversion in plasma, after the gavage administration, 
which may be attributed to low oral bioavailability (2-
6% for (S)-YK-4-279 and 8-15% for (R)-YK-4-279) and 
much slower elimination of YK-4-279 compared to the 
IV administration. Importantly, no enantioconversion 
was seen in the tumors. Taken together, these results 
suggest that the chirality of YK-4-279 does not change 
in the plasma or tumor tissues. The conversion in the 
urine  indicates  either  a  tissue-specific  presence  of  an 
enzyme that isomerizes YK-4-279 or a gastric effect 
that alters compound structure. Additional experiments 
testing biospecificity are necessary to further study the 
pharmacokinetics of (S)-YK-4-279 in vivo to advance the 
small molecule to clinical trials. Although xenograft mice 
treated with YK-4-279 exhibited no toxicity when treated 
with 75 mg per kg body weight[14], separating out the 
inactive enantiomer may allow for a reduction in dosage 
or an increased effect. 
ETS rearrangements are present in 40-70% of 
all prostate cancers, including those that are the most 
clinically aggressive[26-28]. These aggressive prostate 
cancers fuse the promoter of TMPRSS2, an androgen 
responsive gene, to an ETS family transcription factor, 
such as ETV1 or ERG[29], both of which have also been 
identified in joining to EWS in ESFT to form an oncogenic 
fusion protein[30-32]. Recent experiments from our group 
have also indicated that YK-4-279 is able to inhibit ERG 
and ETV1 fusion-positive prostate cancer cell lines[33], 
and the activity and function of the enantiomers should 
be further investigated in prostate cancer. Our data 
support the ability to disrupt a critical oncogenic protein-
protein interaction with YK-4-279 and the importance of 
enantiospecificity in disrupting EWS-FLI1 from RHA. A 
small molecule targeted to the ETS family of transcription 
factors with minimal side effects would be an important 
development in treatment for patients with ESFT and other 
ETS-family oncogenic fusion proteins.
MATERIALS AND METHODS
Separation of YK-4-279
The chemical and chiral HPLC analyses were 
performed using Waters XBridge C18 (250mm x 4.6mm) 
and Chiral Technologies Chiralpak AD (250mm x 4.6mm) 
columns, respectively. The enantiomers were resolved by 
preparative HPLC using a Chiralpak AD column (250mm 
x 77mm) packed in-house using a Varian DynamaxTM 
Rampak Column Packing Station model 41.4/77. Mobile 
phase was 60% 2-propanol in heptane and flow rate was 
maintained at 250ml/min. All mobile phase batches were 
premixed by volume. Sample solution was prepared 
for  purification  by  dissolving  the  sample  in  10:40:50 
dichloromethane/reagent alcohol/heptane. The fractions 
collected during the purification were transferred to round 
bottom  flasks  and  evaporated  using  mild  temperature 
conditions (30 – 35°C) until all solvent was removed. The 
analytical HPLC system used for method development 
and sample analyses was a Waters 2695 Alliance Systems 
coupled to a Waters 996 Photo Diode (PDA) detector. 
Preparative HPLC separations were performed using a 
Waters Delta Prep 2000/4000 equipped with #7 pump 
heads coupled to a Waters 484 UV-Vis detector. Optical 
rotation analyses were performed using a Perkin-Elmer 
Model 343 Polarimeter with c = 10 mg/ml in methanol 
and T = 25°C.
Resolution and Crystallography of YK-4-279
Crystals suitable for x-ray diffraction experiments 
were obtained through slow evaporation of a solution 
containing ethyl acetate. The diffraction experiments 
were performed at 100K on a Rigaku R-axis Rapid Oncotarget 2012; 3:  172-182 180 www.impactjournals.com/oncotarget
diffactometer, equipped with a Mo Kα radiation source 
(60kV, 40mA). HKL-2000 was used for control of the data 
collection as well as data reduction[34]. The structure was 
solved and refined by the HKL-3000SM system, which 
is integrated with SHELXS, SHELXL[35], and 0[36, 
37]. Absolute configurations of both compounds were 
determined using anomalous dispersion. Both compounds 
crystallized in space group P1 with five molecules of 
the YK-4-279 and disordered solvent molecules in the 
asymmetric unit.
Small Molecule Circular Dichroism
Circular dichroism was studied using 100µM 
YK-4-279 and 50µM of each enantiomer in a buffer 
containing 1% ethanol, 5mM sodium phosphate, and 
50mM potassium fluoride, pH 7.4. Data is averaged from 
5 or more independent scans. Scans were performed on a 
Jasco J-715 spectropolarimeter from 400 – 190 nm with a 
bandwidth of 5.0nm, a response of 8 seconds, and a scan 
speed of 50 nm/minute.
ELISA
EWS-FLI1 was used to coat the surface of a 96 
well plate (MaxiSorb) at a concentration of 150ng/
well in 100µL buffer containing 20mM Tris, 500mM 
sodium chloride, and 1M imidazole. Following overnight 
incubation, the plate was blocked with 4% BSA in PBS 
and washed with PBS + 0.1% Tween-20. Small molecules 
were added at concentrations of 1µM, 3µM, 10µM, and 
30µM, followed by RHA (300ng/well) and allowed 
to incubate overnight. Following washing, incubation 
with RHA antibody (Everest) and anti-goat secondary, 
protein binding was detected using a TMB Peroxidase 
EIA  Substrate  Kit  (Bio-Rad)  per  the  manufacturer’s 
instructions.
Quantitative RT-PCR
A673i cells[38] were treated with 1µM small 
molecule for 8 hours. Positive control cells were treated 
with tetracycline for 72 hours to knock down expression 
of EWS-FLI1. Total RNA was extracted using an 
RNeasy Micro Kit (Qiagen) and reverse transcribed 
using the Transcriptor First Strand cDNA Synthesis Kit 
(Roche) per the manufacturer’s instructions. qPCR was 
performed using an Eppendorf Mastercycler Realplex 
with FastStart Universal SYBR Green Master with ROX 
(Roche) with primers for 18S, CyclinD1a, and CyclinD1b. 
Data were analyzed for expression relative to 18S using 
the comparative Ct method. Data from four separate 
experiments performed in duplicate were averaged.
Immunoprecipitation and Western Blotting
TC32 were grown to ~70% confluency and cells 
were treated for 15 hours with small molecule. Nuclear 
lysate was collected using the Active Motif Magnetic 
Co-IP Kit (Active Motif). Protein concentration was 
determined using bicinchoninic acid protein assay for 
each lysate (Pierce) and lysate was bound to 1µg of 
antibody overnight at 4C on a rotating axis with addition 
of same concentration of small molecule as used for 15 
hour treatment. Magnetic beads (Active Motif) were 
added to the lysates and tumbled for 2 hours at 4C. 
Immunoprecipitated proteins were resolved using 10% 
PAGE  and  transferred  to  a  polyvinylidene  difluoride 
membrane (Millipore). Membranes were blocked in 
5% nonfat dry milk in TTBS (20mM Tris-HCl, 150mM 
NaCl, 0.5% Tween 20) for 2 hours. FLI1 (Santa Cruz 
Biotechnologies) and RHA (Abcam) antibodies were used 
at 1:1000 dilutions in 5% nonfat dry milk for 2 hours. 
Horseradish peroxidase-linked anti-rabbit antibody (GE 
Healthcare) was added for 1 hour. Detection was carried 
out using Millipore Immobilon Western Chemiluminescent 
HRP Substrate per the manufacturer’s instructions 
(Millipore Corp.). Chemiluminescence was detected 
using a Fujifilm LAS-3000 imaging system. Densitometry 
values were obtained using ImageJ software.
Reporter Assay
Cells were transiently transfected with the NR0B1 
luciferase reporter[20] and full length EWS-FLI1 into 
COS7 cells with Fugene-6 (Roche) according to the 
manufacturer’s protocol. Two hours after transformation, 
cells were treated with 0.3, 1, and 3µM of YK-4-279, (S)-
YK-4-279, and (R)-YK-4-279. Luciferase activity was 
measured 16 hours after treatment. Protein concentration 
was normalized by absorbance at 280nm. All luciferase 
assays were performed using a luciferase assay kit 
according to the manufacturer’s protocol (Promega).
Cellular Proliferation Assays
TC32, TC71, RDES, MMH-ES-1, STA-ET 7.2, 
A4573, and PC3 cells were grown in RPMI with 10% FBS 
and 1% HEPES. SKES cells were grown in McCoy’s 5A 
medium with 15% FBS. MCF7, MDA-MB-231, PANC1, 
and ASPC1 cells were grown in colorless DMEM with 
10% FBS. Cells were grown at a plating density of 5,000 
– 15,000 cells/well, depending on cell line, in a 96-well 
plate. Small molecule or vehicle alone (DMSO) were 
added to cells in appropriate growth media the day after 
plating. After three days, viable cells were quantified using 
WST (Roche) according to the manufacturer’s protocol. 
IC50 values were calculated by sigmoidal dose-response Oncotarget 2012; 3:  172-182 181 www.impactjournals.com/oncotarget
curve fit using Prism Graphpad 4.0.
Caspase-3 Activity
Cells were plated at 100,000 – 200,000 cells/well, 
depending on cell line, in a 12 well plate. Small molecule 
was added the following day. 18 hours later, lysates were 
collected using the manufacturer’s protocol for the AC-
DEVD-AMC  substrate  (BD  Bioscience  Pharmingen). 
Caspase-3 substrate was incubated for 2 hours with 
protein lysate and fluorescence from cleaved substrate 
was measured in a fluorimeter. Fluorescent signal was then 
normalized to protein lysate via BCA assay.
Pharmacokinetic Analysis
All pharmacokinetic studies were performed 
using Sprague-Dawley rats. Nine rats per gender were 
assigned to nine dose groups, which received either a 
single IV injection of YK-4-279, (S)-YK-4-279, or (R)-
YK-4-279 at a target dose of 25 mg/kg, or a single gavage 
administration of small molecule at a target dose level of 
25 or 50 mg/kg. Plasma was obtained from the rats and 
samples were processed by liquid extraction followed 
by analysis using liquid chromatography with mass 
spectrometry (LC/MS). Average urine concentrations were 
measured at intervals from 0-4, 4-8, and 8-12 hours after 
dosing. 18 Fox Chase SCID Beige mice were injected with 
A4573 cells and received six doses of (S)-YK-4-279 at 
75 mg/kg to determine concentration of small molecule 
in the tumors.
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